Literature DB >> 21697321

Collaborative evaluation of an erythromycin-clindamycin combination well for detection of inducible clindamycin resistance in beta-hemolytic streptococci by use of the CLSI broth microdilution method.

James H Jorgensen1, M Leticia McElmeel, Letitia C Fulcher, Lesley McGee, Sandra S Richter, K P Heilmann, Mary Jane Ferraro, Jean Spargo, Anita Glennen.   

Abstract

Constitutive or inducible clindamycin resistance can occur in beta-hemolytic streptococci due to the presence of an erm gene. The Clinical and Laboratory Standards Institute (CLSI) has recommended a disk approximation test (D-zone test) with erythromycin and clindamycin disks and a single-well broth test combining erythromycin and clindamycin for detection of inducible clindamycin resistance in staphylococci, but only a disk approximation test for the beta-hemolytic streptococci. This collaborative study assessed two different erythromycin and clindamycin concentration combinations in single wells (1 μg/ml + 0.25 μg/ml [erythromycin plus clindamycin] and 1 μg/ml + 0.5 μg/ml) with three different brands of Mueller-Hinton broth supplemented with 3% lysed horse blood for testing of frozen panels prepared for this study. All labs performed the D-zone test as described by the CLSI. A total of 155 nonduplicate streptococcal isolates (50 group A, 48 group B, 28 group C, and 29 group G isolates) were tested; 99 isolates showed inducible resistance by the D-zone test. There were some differences noted based upon the test medium. The sensitivity of the erythromycin plus clindamycin combination of 1 μg/ml + 0.25 μg/ml was 91 to 100%, while the sensitivity of the combination of 1 μg/ml + 0.5 μg/ml was 95 to 100%. Specificity overall was 98%. The slightly higher sensitivity of the combination of 1 μg/ml + 0.5 μg/ml is recommended. This study has demonstrated that a single-well microdilution test incorporating erythromycin and clindamycin in combination is a sensitive and specific indicator of inducible clindamycin resistance and could be included in routine test panels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697321      PMCID: PMC3147760          DOI: 10.1128/JCM.00912-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.

Authors:  Jennifer R Verani; Lesley McGee; Stephanie J Schrag
Journal:  MMWR Recomm Rep       Date:  2010-11-19

2.  Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003.

Authors:  Sandra S Richter; Kristopher P Heilmann; Susan E Beekmann; Norma J Miller; Ashley L Miller; Cassie L Rice; Christopher D Doern; Sean D Reid; Gary V Doern
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

3.  Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?

Authors:  James S Lewis; James H Jorgensen
Journal:  Clin Infect Dis       Date:  2004-12-21       Impact factor: 9.079

4.  Detection of inducible clindamycin resistance in beta-hemolytic streptococci by using the CLSI broth microdilution test and erythromycin-clindamycin combinations.

Authors:  Jason E Bowling; Aaron E Owens; M Leticia McElmeel; Letitia C Fulcher; Monica L Herrera; Brian L Wickes; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

Review 5.  Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.

Authors:  Roland Leclercq
Journal:  Clin Infect Dis       Date:  2002-01-11       Impact factor: 9.079

6.  Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results.

Authors:  M Desjardins; K L Delgaty; K Ramotar; C Seetaram; B Toye
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

7.  Macrolide resistance in Streptococcus pyogenes: prevalence, resistance determinants, and emm types.

Authors:  Athanasios G Michos; Chrysanthi G Bakoula; Maria Braoudaki; Foteini I Koutouzi; Eleftheria S Roma; Anastasia Pangalis; Georgia Nikolopoulou; Elena Kirikou; Vassiliki P Syriopoulou
Journal:  Diagn Microbiol Infect Dis       Date:  2009-04-22       Impact factor: 2.803

8.  Prevalence and mechanisms of erythromycin and clindamycin resistance in clinical isolates of beta-haemolytic streptococci of Lancefield groups A, B, C and G in Seville, Spain.

Authors:  L Merino Díaz; M J Torres Sánchez; J Aznar Martín
Journal:  Clin Microbiol Infect       Date:  2007-11-22       Impact factor: 8.067

9.  Investigation of inducible clindamycin and telithromycin resistance in isolates of beta-hemolytic streptococci.

Authors:  Patti M Raney; Fred C Tenover; Roberta B Carey; John E McGowan; Jean B Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2006-03-20       Impact factor: 2.803

  9 in total
  3 in total

1.  Biographical Feature: James Jorgensen, Ph.D.

Authors: 
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

2.  Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance.

Authors:  Srinivas Acharya Nanduri; Susan Petit; Chad Smelser; Mirasol Apostol; Nisha B Alden; Lee H Harrison; Ruth Lynfield; Paula S Vagnone; Kari Burzlaff; Nancy L Spina; Elizabeth M Dufort; William Schaffner; Ann R Thomas; Monica M Farley; Jennifer H Jain; Tracy Pondo; Lesley McGee; Bernard W Beall; Stephanie J Schrag
Journal:  JAMA Pediatr       Date:  2019-03-01       Impact factor: 16.193

Review 3.  Acquired inducible antimicrobial resistance in Gram-positive bacteria.

Authors:  Scott T Chancey; Dorothea Zähner; David S Stephens
Journal:  Future Microbiol       Date:  2012-08       Impact factor: 3.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.